论文部分内容阅读
目的:探讨分析CDH1基因启动子甲基化与宫颈癌临床病理类型的关系。方法:选取2012年5月~2015年7月我院105例宫颈癌患者为宫颈癌组,同时选取60例正常宫颈组织为正常组,以甲基化特异性聚合酶链反应(MSP)检测CDH1基因启动子Cp G岛甲基化状态及高危型HPV DNA状态,分析CDH1基因甲基化状态与高危型HPV DNA状态及临床病理参数的关系。结果:宫颈癌组CDH1基因启动子甲基化阳性率为56.19%,明显高于正常组的6.67%,具有统计学差异(P<0.05);宫颈癌组的高危型HPV DNA阳性率为84.76%,明显高于正常组的20.00%,具有统计学差异(P<0.05);高危型HPV DNA与CDH1基因启动子甲基化的一致性分析结果具有统计学意义(P<0.05);CDH1基因启动子甲基化率与患者的WHO组织分化程度分级、FIGO分期、组织病理学分型、肿瘤大小有关,差异有统计学意义(P<0.05)。结论:宫颈癌CDH1基因启动子甲基化与WHO组织分化程度分级、FIGO分期、组织病理学分型、肿瘤大小具有关联,并与高危型HPV DNA阳性具有一致性,可以作为宫颈癌诊断和预后评估的参考指标。
Objective: To investigate the relationship between CDH1 promoter methylation and clinicopathological types of cervical cancer. Methods: From May 2012 to July 2015, 105 cases of cervical cancer in our hospital were selected as cervical cancer group. Meanwhile, 60 cases of normal cervical tissue were selected as normal group. Methylation-specific polymerase chain reaction (MSP) was used to detect CDH1 CpG island methylation status of gene promoter and high-risk HPV DNA status, analysis of CDH1 gene methylation status and high-risk HPV DNA status and clinicopathological parameters. Results: The positive rate of CDH1 promoter methylation in cervical cancer group was 56.19%, which was significantly higher than 6.67% in normal group (P <0.05). The positive rate of high risk HPV DNA in cervical cancer group was 84.76% , Which was significantly higher than that of normal group (20.00%) (P <0.05). The consistency analysis of high-risk HPV DNA and CDH1 promoter methylation showed statistical significance (P <0.05). CDH1 gene promoter The methylation rate was related to the degree of WHO histological grade, FIGO stage, histopathological type and tumor size (P <0.05). Conclusion: The promoter methylation of CDH1 gene in cervical cancer is correlated with WHO histological grade, FIGO staging, histopathological classification and tumor size, and is consistent with high-risk HPV DNA positive, which can be used as a diagnostic and prognostic factor for cervical cancer The reference index.